Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute.

Ruiz R, Morante Z, Mantilla R, Mas L, Casanova L, Gomez HL.

An Bras Dermatol. 2017 Sep-Oct;92(5):649-654. doi: 10.1590/abd1806-4841.20176825.

2.

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.

Liang JH, Wang L, Peter Gale R, Wu W, Xia Y, Fan L, Li JY, Xu W.

Blood Cancer J. 2017 Sep 15;7(9):e608. doi: 10.1038/bcj.2017.88. No abstract available.

3.

Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway.

Sui X, Zhang C, Zhou J, Cao S, Xu C, Tang F, Zhi X, Chen B, Wang S, Yin L.

J Exp Clin Cancer Res. 2017 Sep 26;36(1):133. doi: 10.1186/s13046-017-0601-6.

4.

Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.

Yang H, Fu G, Liu J, Da Z, Cheng X, Chen C, Li Y, Fu B, Li X.

Exp Ther Med. 2017 Jul;14(1):567-574. doi: 10.3892/etm.2017.4531. Epub 2017 Jun 1.

5.

Extranodal natural killer/T-cell lymphoma presenting as cavernous sinus syndrome.

Mai HC, Chen DX, Lu D, Zhang YS.

Mol Clin Oncol. 2017 Apr;6(4):543-546. doi: 10.3892/mco.2017.1190. Epub 2017 Mar 9.

6.

The diagnosis and management of NK/T-cell lymphomas.

Tse E, Kwong YL.

J Hematol Oncol. 2017 Apr 14;10(1):85. doi: 10.1186/s13045-017-0452-9. Review.

7.

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type.

Wang JH, Bi XW, Li PF, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ, Wang L.

J Cancer. 2017 Feb 25;8(5):793-800. doi: 10.7150/jca.17766. eCollection 2017.

8.

Two Cases of NK/T Cell Lymphoma Presenting as Chronic Rhinosinusitis.

Thawani R, Seth S, Singh K, Patowary J, Bhadauria M, Das PK.

Indian J Hematol Blood Transfus. 2017 Mar;33(1):148-150. doi: 10.1007/s12288-016-0709-4. Epub 2016 Jul 15.

PMID:
28194077
9.

A Case Report of Primary Nasal Natural Killer (NK)/T-Cell Lymphoma in an African American Patient Presenting with Hemophagocytic Syndrome.

Tan B, Abdelmalek C, O'Donnell JE, Toltaku T, Chaudhry R, Wang JC, Gotlieb V.

Am J Case Rep. 2017 Feb 14;18:160-165.

10.

Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.

Yang CW, Wang CW, Hong RL, Tsai CL, Yao M, Tang JL, Lin CW, Cheng AL, Kuo SH.

J Radiat Res. 2017 Jan;58(1):114-122. doi: 10.1093/jrr/rrw081. Epub 2016 Aug 16.

11.

A Case of Aggressive NK/T-cell Lymphoma/Leukemia with Cutaneous Involvement in Adolescence.

Kim SH, Ko WT, Suh MK, Ha GY, Kim JR.

Ann Dermatol. 2008 Jun;20(2):77-81. doi: 10.5021/ad.2008.20.2.77. Epub 2008 Jun 30.

12.

The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.

Kim TH, Kim JS, Suh YG, Cho J, Yang WI, Suh CO.

Yonsei Med J. 2016 Jul;57(4):846-54. doi: 10.3349/ymj.2016.57.4.846.

13.

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.

Wang JH, Wang L, Liu CC, Xia ZJ, Huang HQ, Lin TY, Jiang WQ, Lu Y.

Oncotarget. 2016 May 17;7(20):29092-101. doi: 10.18632/oncotarget.8647.

14.

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.

Wang JH, Wang H, Wang YJ, Xia ZJ, Huang HQ, Jiang WQ, Lu Y.

Oncotarget. 2016 Jun 7;7(23):35412-22. doi: 10.18632/oncotarget.8643.

15.

Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma.

Küçük C, Hu X, Gong Q, Jiang B, Cornish A, Gaulard P, McKeithan T, Chan WC.

Am J Pathol. 2016 Jun;186(6):1435-41. doi: 10.1016/j.ajpath.2016.02.011. Epub 2016 Apr 7.

16.

Extranodal Natural Killer/T-Cell Lymphoma: A Rare Nasal-Type Case.

Sarıbacak Can E, Okutan H, Albayrak M, Han Ü.

Turk J Haematol. 2016 Mar 5;33(1):74-5. doi: 10.4274/tjh.2015.0169. No abstract available.

17.

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.

Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS.

Blood Res. 2015 Dec;50(4):254-6. doi: 10.5045/br.2015.50.4.254. Epub 2015 Dec 21. No abstract available.

18.

Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Geng L, Wang X.

Int J Clin Exp Med. 2015 Sep 15;8(9):14656-71. eCollection 2015. Review.

19.

The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia.

Zaheen A, Delabie J, Vajpeyi R, Frost DW.

BMJ Case Rep. 2015 Nov 26;2015. pii: bcr2015212103. doi: 10.1136/bcr-2015-212103.

20.

Nasal septal perforation associated with pyoderma gangrenosum.

McConnell B, Said MS, Ramakrishnan VR.

Allergy Rhinol (Providence). 2015 Jan;6(2):122-4. doi: 10.2500/ar.2015.6.0118.

Supplemental Content

Support Center